08Mar/19
ADC-Polatuzumab Vedotin targeting CD79b has been prioritized by FDA in the United States
Roche recently announced that the Food and Drug Administration (FDA) has accepted the biological product licensing application (BLA) of the antibody drug conjugate (ADC) Polatuzumab Vedotin and granted priority review qualifications forRead More…